Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2026-04-27 @ 3:42 AM
Study NCT ID:
NCT02319005
Status:
COMPLETED
Last Update Posted:
2018-07-18
First Post:
2014-12-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Sponsor:
Alnylam Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | View |
| None | Amyloidosis, Hereditary | View |
| None | Amyloid Neuropathies, Familial | View |
| None | Amyloid Neuropathies | View |
| None | Amyloidosis, Hereditary, Transthyretin-Related | View |
| None | Familial Transthyretin Cardiac Amyloidosis | View |